LIN28B and medulloblastoma: Taken together, our data support the hypothesis that LIN28B and its downstream target PBK are important regulators of Group 3 medulloblastoma cell proliferation and that targeting the LIN28B–PBK axis with pharmacologic therapy is plausible.